CURRICULUM VITAE

Key Accomplishments

- Project management with emphasis on preclinical, clinical and regulatory topics
- Well experienced in infectious diseases, oncology and immunology
- Lecturer for immunology/infectious diseases at the TU Munich (Germany)
- Cross-functional management activities with multiple stakeholders (e.g. business development, R&D, regulatory affairs)
- Medical/scientific assessment of novel drugs and biopharmaceuticals
- Scientific contributions to the MAA dossier for anti-EpCAM x anti-CD3 trifunctional bispecific antibody Catumaxomab
- More than 90 publications in renowned scientific/medical journals and books
- Development of a novel recombinant BCG vaccine strain with listeriolysin expression for tuberculosis prevention
- Very good English, strong organizational, communicational and IT skills

Professional Experiences

Since 07.2015	**Consultant at P.SS.T. Pharma Scientific Services Team (Munich, Germany)**
07.2014 - 06.2015	**Advanced training in *Strategic Management* / *Business English* / *Quality Management* (Nuremberg, Germany)**
01.2007 - 06.2014	**Head of Scientific Affairs** **TRION Pharma GmbH, Munich, Germany** **Business area: Biotechnology** **TRION Research GmbH, Planegg, Germany (in charge of TRION Pharma GmbH)** **Business area: R&D services** <u>Responsibilities</u> o Management of preclinical/clinical development projects of four trifunctional bispecific antibodies towards tumor therapy (e.g. anti-CD20 x anti-CD3 FBTA05/Bi20, anti-HER2/neu x anti-CD3 Ertumaxomab, anti-GD2 x anti-CD3 Ektomun or anti-EpCAM x anti-CD3 Catumaxomab) o Medical science management and medical advisor activities o Identification of and communication with KOLs o Raising funds from national and European authorities o Contact to regulatory agencies (e.g. IB, CTD) o Budget responsibility o Cooperation with companies, Helmholtz-Institutes and clinics o Composing of patent applications and responses to office actions o Preparing scientific original and review publications o Writing product and company information (brochures, flyers etc.)

01.2003 - 12.2006

Head of Scientific Affairs
responsif GmbH, Erlangen, Germany
Business area: Biotechnology

Responsibilities

- Coordination and project management of medical research projects "*polyoma virus-like-particles and annexin-V*"
- Raising funds from national and European authorities
- Budget responsibility
- Cooperation with clinic centers
- Composing patent applications and responses to office actions
- Preparing scientific original and review publications
- Writing product and company information
- Responsible for scientific national/international company communication

10.2000 - 12.2002

Head of Business Unit "Molecular Therapy"
november AG, Erlangen, Germany
Business area: Biotechnology/diagnostics

Responsibilities

- Translational research (immunodiagnostics, oncology and veterinary medicine)
- Leadership, planning, coordination and documentation of research projects "polyoma virus-like-particles and annexin-V and ImmunoTrack (incl. rapid test development, lateral flow assay)"
- Raising funds from national authorities and budget responsibility
- Cooperations with companies and clinic centers
- Preparing scientific original and review publications

03.1997 - 09.2000

Group Leader
Max-Planck-Institute for Infection Biology, Berlin, Germany
Department for Immunology

Responsibilities

Development of a novel recombinant BCG vaccine strain with listeriolysin expression for tuberculosis prevention:

- Project management (infectious diseases and vaccines)
- Raising funds from national authorities
- National and international research cooperations
- Preparing scientific original and review publications

03.1992 - 02.1997

Group Leader
University Clinics Ulm, Germany
Department for Immunology

Responsibilities

- Research and development of bacterial viable vaccine strains
- Scientific project management (infectious diseases, vaccines, antibiotics)
- Raising funds from national and international authorities
- National research cooperations
- Title of habilitation: "*A recombinant bacterial delivery system with versatile application possibilities against intracellular pathogens"*
- Degree as university lecturer with current teaching activities for the subject immunology

Temporary Employment Abroad

01.1990 - 02.1992	**Sandoz Research Institute, Vienna, Austria** ▪ PostDoc-position with research activities towards "*HIV-Nef function*"

Education

07.1986 - 12.1989	**University Wuerzburg, Germany** **Graduate thesis (Institute for Microbiology)** o Title of PhD work: "*Transport of hemolysin in Escherichia coli*" o PhD degree (1,0)
11.1980 - 06.1986	**University Wuerzburg, Germany** **Biology diploma study (subjects microbiology, biochemistry, genetics etc.)** o Title of diploma work: "*Nucleotide sequence of a plasmid-encoded hemolysin-determinant and its comparison with a corresponding chromosomal hemolysin sequence of Escherichia coli*" o Degree diploma of biology (1,2)
07.1979 - 09.1980	**Basic Military Service**
08.1970 - 06.1979	**Wigbertschule, Huenfeld, Germany** ▪ University-entrance diploma

Additional Qualifications

Foreign languages:	o Very good English knowledge (TOEIC level: B2) o Basic knowledge in French
Information technology skills:	o Expert knowledge on data bank search (molecular biology, patent affairs, market data) o Excellent knowledge in MS Office
Expert knowledge:	o Proven expertise according § 75 German Medicines Law o Authorization for pathogen handling according German § 44 IfSG o Project leader and authorized person for biological safety according German § 15, 2 (1) Nr. 3 GenTG o Referee (Norwegian Ministry of Research and Education, Editorial Board of *Infection & Immunity*, *European Journal of Immunology*, and for Germany authorities like BMBF as well as DFG) o Member of the editorial board of *Infection & Immunity* (American Society of Microbiology, 1996-2006)
Advanced training (selection):	o Executive training at *november AG* (2001) o FDA rule 21 CFR part 11 training (BioMedion, 2002) o EU-GCP-guide lines (Pharmalog, 2003) o Introduction of clinical trials incl. ICH guidelines, EU directive (GCP) (Colloquium Pharmaceuticum, 2004) o GMP-introduction (QuaSyCon; 2002, 2005) o Investigator-initiated-trials (FORUM, 2008) o Health economy and pricing (FORUM, 2009)